ADZYNMA Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This ADZYNMA market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period was driven by the increasing prevalence of chronic diseases, higher healthcare spending, the expansion of hospital infrastructure, supportive government policies and reimbursement programs, and heightened awareness of innovative therapies.

The projected growth during the forecast period is driven by the rising demand for personalized medicine, increased investment in research and development, a growing focus on outpatient care, expanding adoption of telehealth and remote monitoring, and regulatory approvals for innovative therapies. Key trends expected in this period include the integration of AI in healthcare delivery, increasing adoption of biosimilars, the expansion of home-based treatments, heightened collaborations between pharmaceutical and technology companies, and a shift towards digital therapeutics and monitoring solutions.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the adzynma market in the coming years. Autoimmune disorders occur when the immune system mistakenly targets the body's own tissues, resulting in chronic inflammation and potential damage to multiple organs. Factors such as genetic predisposition, environmental triggers, and lifestyle changes contribute to the rising incidence of these conditions. ADZYNMA is a therapeutic agent designed to modulate immune responses in autoimmune disorders by targeting specific pathways to reduce inflammation and minimize tissue damage. For example, Public Health Scotland reported in July 2023 that newly diagnosed multiple sclerosis (MS) cases increased from 85.7% to 87.2% in 2022, with 491 new cases reported, bringing the total number of cases to 6,359 that year. This growing prevalence underscores the expanding demand for effective treatments like adzynma.

A notable trend in the adzynma market is the emphasis on advancements in biologic drug development to establish a competitive edge. Innovations such as monoclonal antibodies, fusion proteins, and recombinant biologics are transforming treatment approaches by enhancing precision and reducing side effects compared to traditional therapies. For instance, in November 2023, Takeda, a leading biopharmaceutical company based in Japan, announced the U.S. Food and Drug Administration's (FDA) approval of ADZYNMA (ADAMTS13, recombinant-krhn). This approval covers both prophylactic and on-demand treatment for adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). As the first and only FDA-approved recombinant ADAMTS13 (rADAMTS13) protein, ADZYNMA addresses a critical medical need by replacing the deficient ADAMTS13 enzyme in individuals with cTTP, demonstrating its significance in addressing unmet therapeutic requirements.

In February 2024, Takeda, a Japan-based biopharmaceutical leader, entered a strategic partnership with Protagonist Therapeutics to advance the development and commercialization of rusfertide. This collaboration leverages Takeda's proven expertise in rare hematology, highlighted by the recent FDA approval of ADZYNMA for the treatment of congenital thrombotic thrombocytopenic purpura. Protagonist Therapeutics, a US-based biopharmaceutical company, specializes in peptide-based therapeutic solutions.

Key players in the adzynma market is Takeda Pharmaceutical Company Limited.

North America was the largest region in the ADZYNMA market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ADZYNMA market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Adzynma is a medication designed to treat congenital thrombotic thrombocytopenic purpura (cTTP), a genetic disorder caused by mutations in the ADAMTS13 gene, in both adults and children. It aims to offer a cost-effective alternative with comparable efficacy and safety, enhancing access to critical, life-saving treatments.

The primary indications in ADZYNMA include autoimmune diseases, inflammatory diseases, and other conditions. Autoimmune diseases arise when the immune system mistakenly targets the body’s own tissues, resulting in inflammation and potential damage to various organs or systems. The product is distributed through hospitals, clinics, retail pharmacies, and specialty pharmacies, with its end users comprising adult and pediatric patients.

The ADZYNMA market research report is one of a series of new reports that provides ADZYNMA market statistics, including ADZYNMA industry global market size, regional shares, competitors with a ADZYNMA market share, detailed ADZYNMA market segments, market trends and opportunities, and any further data you may need to thrive in the ADZYNMA industry. This ADZYNMA market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ADZYNMA market consists of sales of biologic therapies for autoimmune and inflammatory diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.